Showing results (141-150 of 170) with videos related to

Sort By:
Pageof 17
Cancer Cell|March 31, 2004
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumorsConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.
Oncogene|October 14, 2004
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cellsTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Cancer Research|December 17, 2005
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implicationsYu-Tzu Tai, Xian-Feng Li, Laurence Catley, et al.
Cancer Research|August 17, 2005
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistanceHiroshi Yasui, Teru Hideshima, Noopur Raje, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 30, 2003
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implicationsConstantine S Mitsiades, Nicholas S Mitsiades, Ciaran J McMullan, et al.
Blood|April 2, 2005
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myelomaHiroshi Yasui, Teru Hideshima, Makoto Hamasaki, et al.
Molecular Cancer Therapeutics|January 14, 2009
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivoRenate Burger, Steven Le Gouill, Yu-Tzu Tai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2011
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomideLoredana Santo, Teru Hideshima, Diana Cirstea, et al.
Blood|September 8, 2012
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibitionMichele Cea, Antonia Cagnetta, Mariateresa Fulciniti, et al.
Cancer Cell|November 16, 2005
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibDharminder Chauhan, Laurence Catley, Guilan Li, et al.
Pageof 17